
November 2017: diagnosed with Stage IV, High-Risk Neuroblastoma; Nov 2017-April 2019: completed standard treatment protocol / no evidence of disease; April 2019-April 2021: enrolled in/completed DFMO clinical trial; April 2022: RELAPSE; April 2022-June 2023: completed relapse treatment protocol / no evidence of disease (again); June 2023-June 2024: enrolled in “compassionate use” high-dose DFMO clinical trial; June 2024: RELAPSE #2
Tuesday, March 25, 2025
Wednesday, February 26, 2025
Tuesday, February 11, 2025
Tuesday, January 28, 2025
Wednesday, January 22, 2025
Monday, January 13, 2025
Friday, January 10, 2025
Monday, January 6, 2025
Saturday, December 14, 2024
Monday, December 9, 2024
Friday, November 29, 2024
Friday, November 8, 2024
Monday, November 4, 2024
Monday, October 28, 2024
Monday, October 21, 2024
Monday, October 7, 2024
Saturday, October 5, 2024
Thursday, October 3, 2024
Friday, September 27, 2024
Monday, September 16, 2024
Wednesday, September 11, 2024
Friday, August 23, 2024
Monday, August 19, 2024
Friday, July 26, 2024
Monday, July 22, 2024
Friday, July 19, 2024
Thursday, July 11, 2024
Wednesday, July 3, 2024
Wednesday, June 26, 2024
Monday, March 25, 2024